Rapid switch from intravenous epoprostenol to intravenous Remodulin (treprostinil sodium) in patients with stable pulmonary arterial hypertension in the outpatient clinic: Safety, efficacy and treatment satisfaction
Phase of Trial: Phase IV
Latest Information Update: 20 Jun 2013
At a glance
- Drugs Treprostinil (Primary) ; Epoprostenol
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- Sponsors United Therapeutics Corporation
- 10 Jun 2017 Biomarkers information updated
- 01 Feb 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 09 Apr 2008 New trial record.